Psychopharmacology and Psychiatry Updates

In this episode, we explore the paradox of pharmacogenetic testing with Dr. Chris Aiken: why do these tests consistently fail in clinical trials despite showing promise in understanding drug metabolism? Could industry bias and statistical noise be masking the truth about personalized psychiatric medicine?
Faculty: Chris Aiken, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.75 CME: The Role of Genetic Testing in Psychiatry
Pharmacogenetic Panels: Do They Really Work?

In this episode, we explore how Lurasidone at lower doses (20-60 mg/day) effectively treats both depression and anxiety in bipolar I disorder. Why does the lower dose range outperform higher doses for patients with severe anxiety? Discover the surprising dose-dependent effects and metabolic advantages that make this a game-changer.
Faculty: Kristin Raj, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here.
Earn 0.75 CMEs: Quick Take Vol. 77
Is Lurasidone Effective for Bipolar Depression with Comorbid Anxiety?

In this episode, we explore how GLP-1 agonists—the weight loss medications making headlines everywhere—could revolutionize management of antipsychotic-induced weight gain. Can these drugs help patients lose weight while maintaining psychiatric stability? We examine the latest evidence and discuss practical implementation strategies for your practice.
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 76
Antipsychotic-Induced Weight Gain: Are GLP-1 Agonists Effective?

In this episode, we explore pharmacogenetics-guided dosing strategies with Dr. Chris Aiken. What if your patient's treatment failure isn't about the wrong medication, but the wrong dose? Discover how genetic testing reveals whether patients are poor or rapid metabolizers and learn the specific dosing adjustments that can transform outcomes.
Faculty: Chris Aiken, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.75 CME: The Role of Genetic Testing in Psychiatry
Pharmacogenetics-Guided Dosing: Strategies for Poor and Rapid Metabolizers

In this episode, we explore the newly published INTEGRATE guidelines—the first truly international algorithm for schizophrenia treatment. Should clozapine be started after just 12 weeks? When are long-acting injectables appropriate for first-episode patients? Discover how these guidelines aim to standardize quality care worldwide.
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CME: Quick Take Vol. 77
INTEGRATE: New Schizophrenia Treatment Guidelines